Riskpilot← Back to searchSign inGet full accessCellcolabs AB
ABActiveOrg 5593126955Scheeles Väg 5Research and experimental development on natural sciences and engineering · NACE 7210Est. 202165 employees
Revenue 2024
SEK 15,3M
+539% vs 2023
EBITDA margin
-592.1%
-54% vs 2023
Equity ratio
43.6%
Financial strength
Net profit 2024
SEK -91,8M
-54% vs 2023
| Revenue | SEK 15,3M | +539% |
| EBITDA | SEK -90,4M | -54% |
| Net profit | SEK -91,8M | -54% |
| Total assets | SEK 64,7M | +79% |
| Equity | SEK 28,2M | -2% |
| Employees | 65 | — |
Legal name
Cellcolabs AB
Org number
5593126955
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
16 april 2021
Share capital
SEK 53 327
Employees
65 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av en av ledamöterna i förening med Hallman, Petter Emanuel Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska, direkt eller indirekt genom hel- eller delägda bolag, producera och sälja cellprodukter för användning i samband med behandling av olika sjukdomstillstånd. Bolaget kommer även att bedriva forskning och processutveckling inom cellproduktion. Bolaget får dessutom handla med noterade och onoterade värdepapper.
Address
Scheeles Väg 5
Email
petter.hallman@cellcolabs.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 92 | 2 389 | 15 270 |
| Staff expenses | — | — | −26 174 | −50 538 |
| EBITDA | −5 732 | −37 522 | −58 627 | −90 419 |
| Depreciation & amort. | −96 | −1 532 | −1 867 | −2 260 |
| EBIT | −5 828 | −39 054 | −60 494 | −92 679 |
| Net financials | — | 132 | 1 043 | 903 |
| Profit before tax | −5 828 | −38 922 | −59 451 | −91 776 |
| Tax | −0 | −0 | — | — |
| Net profit | −5 828 | −38 922 | −59 451 | −91 776 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 17 073 | 51 011 | 36 068 | 64 699 |
| Equity | 14 199 | 39 287 | 28 666 | 28 182 |
| Long-term debt | 0 | 0 | — | — |
| Short-term debt | 2 875 | 11 724 | 7 402 | 36 517 |
| Total debt | 2 875 | 11 724 | 7 402 | 36 517 |
EBITDA margin
-592.1%
This company
15.8%
Market median
-3847% vs market
20212024
Equity ratio
43.6%
This company
38.2%
Market median
+14% vs market
20212024
Return on equity
-325.7%
This company
18.4%
Market median
-1870% vs market
20212024
Net profit margin
-601.0%
This company
8.1%
Market median
-7520% vs market
20212024
Asset turnover
0.24×
This company
1.12×
Market median
-79% vs market
20212024
Debt / equity
1.30×
This company
0.62×
Market median
-110% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-04-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SJ Chief Auditor | Chief Auditor | 2021 | — | — |
IS External Signatory | External Signatory | 2021 | — | — |
PE Chief Executive Officer | Chief Executive Officer | 2026 | — | — |
MJ Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2025 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Takura AB | Company | 70.0% | 70.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Takura AB
Cellcolabs AB Board members of Cellcolabs AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sandra Jenny Carina Lindvall | Chief Auditor | 0 companies |
| Ida Sofia Elisabeth Duprez | External Signatory | 0 companies |
| Petter Emanuel Hallman | Chief Executive Officer | 0 companies |
| Mattias Jens Edvard Bernow | Chief Executive Officer | 0 companies |
| Kayaan Keki Unwalla | Deputy Board Member | 0 companies |
| Erik Engellau-Nilsson | Board of Directors | 0 companies |
| Håkan Thore Hallberg | Board of Directors | 0 companies |
| Louis Richard Hugo De Geer | Board of Directors | 0 companies |
| Robert James Mark Hain | Board of Directors | 0 companies |
| Per Jonas Båtelson | Board of Directors | 0 companies |
| Miriam Beth Addelston Donaldson | Board of Directors | 0 companies |
| Eva Maria Halling Rankka | Chairman | 0 companies |
| Simon Lindfors | Board of Directors | 0 companies |